The drug, called amycretin and codenamed NN9487, is a dual agonist that targets both GLP-1 and amylin and is being developed in both oral and subcutaneous injection formulations. The oral form has ...

Novo Nordisk itself has a new and improved drug under development. Amycretin saw some participants lose 22% of their body weight in an early trial, though it is some years from being ready for the ...

This is on top of NVO's promising pipeline, amycretin, offering accelerated weight loss results compared to CagriSema and LLY's Zepbound/ Retatrutide. Even so, we had believed that FY2025 was ...

Novo Nordisk itself has a new and improved drug under development. Amycretin saw some participants lose 22% of their body weight in an early trial, though it is some years from being ready for the ...

Novo Nordisk's 2024 earnings exceeded estimates, with 25% revenue growth and strong performance in diabetes, obesity, and rare disease segments. The market overreacted to CagriSema trial results ...

Pfizer is advancing on a broad front in its attempt to catch up with Novo Nordisk and Eli Lilly in the obesity drug category – but has now decided on a lead candidate. The company said that ...

Invest in the best stocks under $50 with Interactive Brokers for fast trade execution. You don’t need thousands of dollars in the bank to get started investing. Just $50, or less, can help you ...

Under the programm Bagsværd, Denmark, 24 January 2025 – Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 and amylin receptor ...

We recently published a list of 10 Best Annual Dividend Stocks To Buy Now. In this article, we are going to take a look at where Roche Holding AG (OTC:RHHBY) stands against other best annual ...

In anticipation of the Delhi election results, Bharatiya Janata Party (BJP) spokesperson Gaurav Bhatia expressed gratitude to the public, acknowledging a 'clear message' from voters who desire a ...

Koninklijke Ahold Delhaize N.V. €33.63-2.05-5.75% ...